Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · IEX Real-Time Price · USD
12.40
-0.06 (-0.48%)
Jul 22, 2024, 9:30 AM EDT - Market open
Avalo Therapeutics Employees
Avalo Therapeutics had 19 employees as of December 31, 2023. The number of employees decreased by 1 or -5.00% compared to the previous year.
Employees
19
Change (1Y)
-1
Growth (1Y)
-5.00%
Revenue / Employee
$76,316
Profits / Employee
-$7,519,947
Market Cap
12.82M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Universe Pharmaceuticals INC | 225 |
Psychemedics | 116 |
Addex Therapeutics | 23 |
NEXGEL | 19 |
NeuroSense Therapeutics | 18 |
GeoVax Labs | 17 |
QT Imaging Holdings | 14 |
Kiora Pharmaceuticals | 12 |
AVTX News
- 6 days ago - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewsWire
- 13 days ago - Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewsWire
- 27 days ago - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - GlobeNewsWire
- 5 weeks ago - Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit - GlobeNewsWire
- 2 months ago - Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Avalo Therapeutics Appoints Biotech Leaders to Board of Directors - GlobeNewsWire
- 4 months ago - Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip? - Invezz
- 4 months ago - Avalo Reports 2023 Financial Results and Provides Business Updates - GlobeNewsWire